• Dépistage, diagnostic, pronostic

  • Évaluation des technologies et des biomarqueurs

  • Colon-rectum

A Modified TNM Classification for Primary Operable Colorectal Cancer

Menée à partir des données des registres du cancer portant sur 45 379 patients atteints d'un cancer colorectal de stade I à III et à partir de données portant sur 10 902 patients supplémentaires, cette étude évalue, par rapport à la huitième édition du système de classification TNM de l'"American Joint Committee on Cancer", la performance d'un système de classification TNM modifié pour établir un pronostic

The American Joint Committee on Cancer (AJCC) 8th tumor/node/metastasis (TNM) classification for colorectal cancer (CRC) has limited ability to predict prognosis.We included 45,379 eligible stage I-III CRC patients from the Surveillance, Epidemiology, and End Results Program. Patients were randomly assigned individually to a training (N =31,772) or an internal validation cohort (N =13,607). External validation was performed in 10,902 additional patients. Patients were divided according to T and N stage permutations. Survival analyses were conducted by a Cox proportional hazard model and Kaplan-Meier analysis, with T1N0 as the reference. Area under receiver operating characteristic curve (AUC) and Akaike information criteria (AIC) were applied for prognostic discrimination and model-fitting, respectively. Clinical benefits were further assessed by decision curve analyses.We created a modified TNM (mTNM) classification: stages I (T1-2N0-1a), IIA (T1N1b, T2N1b, T3N0), IIB (T1-2N2a-2b, T3N1a-1b, T4aN0), IIC (T3N2a, T4aN1a-2a, T4bN0), IIIA (T3N2b, T4bN1a), IIIB (T4aN2b, T4bN1b), and IIIC (T4bN2a-2b). In the internal validation cohort, compared to the AJCC 8th TNM classification, the mTNM classification showed superior prognostic discrimination (AUC = 0.675 vs. 0.667, respectively; two-sided P <0.001) and better model-fitting (AIC = 70,937 vs. 71,238, respectively). Similar findings were obtained in the external validation cohort. Decision curve analyses revealed that the mTNM had superior net benefits over the AJCC 8th TNM classification in the internal and external validation cohorts.The mTNM classification provides better prognostic discrimination than AJCC 8th TNM classification, with good applicability in various populations and settings, to help better stratify stage I-III CRC patients into prognostic groups.

JNCI Cancer Spectrum , article en libre accès, 2019

Voir le bulletin